Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 3093

Dual-targeting liposome-based drug delivery system

Inventors: Marsha Moses, Peng Guo

Invention Types: Therapeutics

Research Areas: Oncology/Hematology

Keywords: Animal Model (mouse), Drug Delivery, Gene expression, Receptor/Ligand, Cell Signaling, Drug Design, Platform

Invention Description:

A major challenge in cancer treatment is discriminating malignant cancer cells from normal cells. “Cancer-targeting” liposomes have been engineered to facilitate the specific recognition of cancer, but have had limited success due to “off-target” effects.

Dr. Marsha Moses and collaborators have developed a novel liposome delivery system that exploits the overexpression of cell surface proteins on cancer cells by recognizing and complementing their molecular density. These dual complementary liposomes (DCLs) have a double therapeutic effect on cancer cells: first, they facilitate targeted delivery of a drug to cancer cells; second, they neutralize the signaling cascades triggered by cell surface proteins to inhibit cell invasion and proliferation.

Proof-of-concept studies have been performed with triple negative breast cancer (TNBC) cells. Doxorubicin-loaded DCLs with conjugated ligands targeting ICAM1 and EGFR are more efficiently internalized by TNBC cells in vitro than single-target liposomes, efficiently and specifically kill the malignant cells, and reduce proliferation and invasion. Furthermore, the DCLs were pre-clinically validated in an orthotopic mouse model in which they inhibited tumor growth and metastasis while increasing survival.

The DCL platform can be customized to target other cancers and deliver a variety of payloads. Using a combination of proteomic and genetic screening, a truly personalized and cell-specific therapeutic could be created to improve outcomes for cancer patients.

Applications:

• Novel TNBC therapy that is highly precise and effective
• Platform to develop targeted therapeutics for other cancers

Competitive Advantages:

• A customizable system based on proteomic and genetic screening to optimize target combinations for specific cancer sub-types
• DCL’s are engineered to provide specific and cooperative adhesion force that are not provided by existing methods
• Synergistic effect of drug cargo and cell signaling inhibition of DCLs

Business Opportunity:

License, sponsored research, collaboration

IPStatus: Pat. Pend.